Eli Lilly’s oral GLP-1RA gains fourth Phase III type 2 diabetes win
The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key secondary endpoints.
16 October 2025
16 October 2025
The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key secondary endpoints.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.